by Roman Fabbricatore
Fertility and sexual health services appear to be offered to cancer survivors less often than other services at CoC-accredited practices.
Enforcing survivorship standards may help centers provide services to address the needs of cancer survivors, according to … Read more
by Linda Wang
Physical activity can have many benefits for cancer survivors, from improving their quality of life to potentially making it less likely that their disease will come back. Yet studies have shown that many cancer survivors struggle to … Read more
—No difference in adverse events, clinical benefit, OS for patients with or without waivers
by Charles Bankhead
Patients who received protocol waivers in a clinical trial of targeted anticancer therapy had outcomes similar to those who met all enrollment criteria, a large retrospective review showed.
Patients who received waivers had a clinical benefit rate … Read more
by Aaron Tallent
Key Points:
Led by Dr Melissa Merritt and Dr Nicola Meagher from the Daffodil Centre … Read more
by Van Andel Research Institute
Two types of endometriosis-related ovarian cancer arise from the same cells but likely at different stages of the menstrual cycle—a nuance that significantly influences treatment response, reports a recent study led by Van Andel Institute … Read more
Studying human genes to explore how changes in DNA might influence the onset, progression, and treatment of cancer has become a cornerstone in today’s world. Over the past 25 years, progress has ramped up due to technology advances, increased access … Read more
Clearity’s Perspective: Clearity knows that making decisions about continuing treatment when facing advanced ovarian cancer is complicated. Given the difficulty of these decisions, this article suggests having goals-of-care conversations with your medical providers when deciding whether or not to continue … Read more
by Josh Friedman
An artificial intelligence-driven algorithm used a novel liquid biopsy assay to differentiate women with ovarian … Read more
Clearity’s Perspective: This article highlights the importance of learning ways to cope with and manage stress after an ovarian cancer diagnosis. The study, performed only on mice, suggests that there may be a link between overproduction of stress hormones and … Read more
Clearity’s Perspective: At the SGO meeting several presentations described how circulating tumor DNA (ctDNA) may be a new, personalized, sensitive tool to help evaluate treatment de-escalation, monitor minimal residual disease (MRD), and track treatment response in ovarian cancer. The application … Read more
Clearity’s Perspective: Previous research in different types of cancer has suggested that there is a relationship between a cancer patient’s gut microbiota (microorganisms that live in the digestive tract) composition and the response to immune checkpoint inhibitor therapy; however,
… Read moreBy Mike Basset
Risk management strategies including bilateral salpingo-oophorectomy (BSO) for ovarian cancer and MRI surveillance for breast cancer were associated with a significant reduction in mortality for women with BRCA1/2 sequence variations, according to results from two cohort studies … Read more
Clearity’s Perspective: Clearity offers emotional support to people with ovarian cancer and their caregivers through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our team … Read more
By Fay Lin, PhD
A major bottleneck in early detection is the molecular heterogeneity between ovarian cancer (OC) patients, which limits the likelihood of identifying individual biomarkers that are shared among patients. In a new study “A personalized probabilistic … Read more
By Ashling Wahner
Although the antibody-drug conjugate (ADC) mirvetuximab soravtansine-gynx (Elahere) is associated with a high rate of ocular toxicity in patients with folate receptor α (FRα)-positive, platinum-resistant ovarian cancer, the real-world incidence of this adverse effect (AE) in this … Read more
By Erin T. Welsh, MA
Asian, Black and Hispanic women with … Read more
By Rylan DeStefano
An artificial intelligence model called IRON (Integrated Radiogenomics for Ovarian Neoadjuvant therapy) shows an 80% accuracy rate in the prediction of therapy outcomes for patients with ovarian cancer. The artificial intelligence model focuses specifically on the volumetric … Read more
Clearity’s Perspective: Cancer cells that have mutations in BRCA or that are HRD-positive are not able to use the so-called homologous recombination repair pathway to fix mistakes in the cancer cell. These cancer cells become reliant on other repair pathways. … Read more
